Lifeist Wellness Inc. (LFST.V)
CAD 0.04
(0.0%)
CAD 0.04
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.76 Million CAD | 20.19% |
| 2022 | -17.44 Million CAD | 32.55% |
| 2021 | -20.25 Million CAD | 12.27% |
| 2020 | -23.66 Million CAD | -412.66% |
| 2019 | -25.38 Million CAD | 136.48% |
| 2018 | -22.1 Million CAD | -1837.19% |
| 2017 | -7.69 Million CAD | 203.27% |
| 2016 | -1.16 Million CAD | -276.22% |
| 2015 | - CAD | 198.97% |
| 2014 | -667.18 Thousand CAD | -78.49% |
| 2013 | -304.9 Thousand CAD | -4.26% |
| 2012 | -467.75 Thousand CAD | -150.12% |
| 2011 | -2.21 Million CAD | 261.69% |
| 2010 | -442.4 Thousand CAD | -204.67% |
| 2009 | -145.2 Thousand CAD | -26.76% |
| 2008 | -24.41 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1 Million CAD | 69.22% |
| 2024 Q3 | -1.2 Million CAD | -21.64% |
| 2024 Q2 | 500 Thousand CAD | 52.39% |
| 2023 Q3 | -2.06 Million CAD | 11.82% |
| 2023 Q2 | -2.33 Million CAD | 20.21% |
| 2023 Q1 | -2.93 Million CAD | 23.03% |
| 2023 FY | - CAD | 20.19% |
| 2023 Q4 | -5 Million CAD | -142.4% |
| 2022 Q4 | -3.8 Million CAD | -94.98% |
| 2022 Q2 | -4.53 Million CAD | -7.2% |
| 2022 Q1 | -4.23 Million CAD | -15.68% |
| 2022 FY | - CAD | 32.55% |
| 2022 Q3 | -1.95 Million CAD | 56.93% |
| 2021 Q4 | -3.65 Million CAD | 31.57% |
| 2021 Q2 | -5.53 Million CAD | 5.4% |
| 2021 Q1 | -5.85 Million CAD | 18.52% |
| 2021 FY | - CAD | 12.27% |
| 2021 Q3 | -5.34 Million CAD | 3.48% |
| 2020 Q2 | -5.38 Million CAD | 1.3% |
| 2020 Q1 | -5.45 Million CAD | -117.02% |
| 2020 Q3 | -4.09 Million CAD | 23.95% |
| 2020 Q4 | -7.18 Million CAD | -75.47% |
| 2020 FY | - CAD | -412.66% |
| 2019 Q3 | -5.87 Million CAD | 30.33% |
| 2019 Q1 | -10.12 Million CAD | 20.2% |
| 2019 Q2 | -8.43 Million CAD | 16.76% |
| 2019 Q4 | 32.04 Million CAD | 645.63% |
| 2019 FY | - CAD | 136.48% |
| 2018 Q1 | -3.25 Million CAD | -13.57% |
| 2018 FY | - CAD | -1837.19% |
| 2018 Q4 | -12.69 Million CAD | -60.96% |
| 2018 Q3 | -7.88 Million CAD | -16.08% |
| 2018 Q2 | -6.79 Million CAD | -108.75% |
| 2017 Q2 | -4.4 Million CAD | -182.76% |
| 2017 Q1 | -1.55 Million CAD | -81.54% |
| 2017 FY | - CAD | 203.27% |
| 2017 Q4 | -2.86 Million CAD | -143.95% |
| 2017 Q3 | 6.52 Million CAD | 248.09% |
| 2016 Q4 | -857.76 Thousand CAD | 1.32% |
| 2016 Q2 | -296.06 Thousand CAD | -395.18% |
| 2016 FY | - CAD | -276.22% |
| 2016 Q1 | -59.79 Thousand CAD | -2.21% |
| 2016 Q3 | -869.24 Thousand CAD | -193.6% |
| 2015 FY | - CAD | 198.97% |
| 2015 Q4 | -58.49 Thousand CAD | -96.62% |
| 2015 Q3 | -29.75 Thousand CAD | 37.04% |
| 2015 Q2 | -47.25 Thousand CAD | -112.88% |
| 2015 Q1 | 366.99 Thousand CAD | 389.24% |
| 2014 Q4 | -126.88 Thousand CAD | 51.31% |
| 2014 FY | - CAD | -78.49% |
| 2014 Q3 | -260.59 Thousand CAD | -30.15% |
| 2014 Q1 | -220.95 Thousand CAD | -856.87% |
| 2014 Q2 | -200.23 Thousand CAD | 9.37% |
| 2013 Q4 | -23.09 Thousand CAD | 64.81% |
| 2013 FY | - CAD | -4.26% |
| 2013 Q1 | -97.72 Thousand CAD | -24.95% |
| 2013 Q2 | -64.12 Thousand CAD | 34.38% |
| 2013 Q3 | -65.62 Thousand CAD | -2.34% |
| 2012 Q4 | -78.2 Thousand CAD | 29.03% |
| 2012 Q1 | 1.26 Million CAD | 784.3% |
| 2012 FY | - CAD | -150.12% |
| 2012 Q3 | -110.2 Thousand CAD | -54.09% |
| 2012 Q2 | -71.51 Thousand CAD | -105.64% |
| 2011 Q1 | -235.09 Thousand CAD | -354.32% |
| 2011 Q3 | -236.17 Thousand CAD | -70.67% |
| 2011 FY | - CAD | 261.69% |
| 2011 Q2 | -138.38 Thousand CAD | 41.14% |
| 2011 Q4 | -185.25 Thousand CAD | 21.56% |
| 2010 FY | - CAD | -204.67% |
| 2010 Q3 | -89.39 Thousand CAD | -37.78% |
| 2010 Q2 | -64.87 Thousand CAD | -64.21% |
| 2010 Q1 | -39.51 Thousand CAD | -5.36% |
| 2010 Q4 | -51.74 Thousand CAD | 42.11% |
| 2009 FY | - CAD | -26.76% |
| 2009 Q3 | -43.24 Thousand CAD | -73.12% |
| 2009 Q4 | -37.5 Thousand CAD | 13.28% |
| 2009 Q2 | -24.97 Thousand CAD | 85.23% |
| 2009 Q1 | -169.11 Thousand CAD | -169.58% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q4 | 243.03 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.68 Million CAD | -376.239% |
| CanadaBis Capital Inc. | 5.67 Million CAD | 324.903% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 324.86% |
| Delivra Health Brands Inc. | 2.35 Million CAD | 642.471% |
| Entourage Health Corp. | -21.39 Million CAD | 40.319% |
| Cannara Biotech Inc. | 17.18 Million CAD | 174.298% |
| Medicure Inc. | 1.27 Million CAD | 1103.124% |
| PharmaCielo Ltd. | -12.01 Million CAD | -6.25% |
| Rubicon Organics Inc. | 1.94 Million CAD | 755.532% |
| BioSyent Inc. | 9.05 Million CAD | 240.984% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -945.887% |